Bristol Myers Squibb said Wednesday that they are discontinuing enrollment in the Phase 3 KarMMa-9 study investigating Abecma in patients with newly diagnosed multiple myeloma. 2seventy CEO Chip Baird ...

(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...

2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma.

CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...

Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.

An international study led by the Spanish National Cancer Research Centre (CNIO) and the 12 de Octubre Hospital in Madrid ...

The Maple Ridge resident was surprised considering, as he has since learned, multiple myeloma is the second most prevalent ...

A group of advanced practice providers discuss treatment options for a woman with newly diagnosed, transplant-ineligible ...

Multiple myeloma (MM) affects white plasma in the bone marrow. Cancerous tumors can weaken the body's immune system, damage ...

Melbourne mum Marlo McCarthy revealed in the Herald Sun on Monday that she has been diagnosed with the same rare blood cancer ...

The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.

After several years spent honing its robotic cell therapy manufacturing system, Multiply Labs has snared its first ...